The U.S. Food and Drug Administration is warning diabetes patients that some drugs could cause a flesh-eating bacterial infection of the genitals, the agency posted on its website Wednesday.
The condition, called Fournier's gangrene, has been reported in connection with sodium-glucose cotransporter-2 inhibitors, the FDA said.
According to the FDA, the drugs help the body lower blood-sugar levels through the kidneys. Excess sugar is excreted in a patient's urine, and urinary tract infections are a known side effect, the FDA said.
TRENDING NOW:
- Skylights 2018: Week 1 high school football scores
- Labor Day 2018 deals and sales from Macy's, Walmart, Best Buy and more
- Police ask for help finding motorcyclist's missing arm after crash
- VIDEO: Father's Facetime Call Saves Young Daughter Trapped in Car with Drunk Woman
- DOWNLOAD the Channel 11 News app for breaking news alerts
SGLT2 inhibitors approved by the FDA include Johnson & Johnson's Invokana, Eli Lilly & Co's Jardiance, as well those from Bristol-Myers Squibb, AstraZeneca Plc, Merck & Co and Pfizer Inc.
Fournier's gangrene is rare but can be a life-threatening bacterial infection, the FDA said. The bacteria usually enters the body through a cut or break in the skin, and then spreads and destroys the flesh it infects.
The FDA said from March 2013 to May 2018, 12 cases of Fournier's gangrene in patients taking one of the inhibitors were identified. The cases included seven men and five women, who all were hospitalized and required surgery.
Cox Media Group
/cloudfront-us-east-1.images.arcpublishing.com/cmg/XCUXZC2XYZHCRGNNGKFEX6U3LQ.png)
